Table 2.
Association of sPD-L1, CTCs, and platinum-resistance/sensitivity status of EOC Patients with 5-year overall survival (OS) (A) and progression-free survival (PFS) (B).
| Parameter | No | Yes | p† | OR (95% CI) | |
|---|---|---|---|---|---|
| (A) | |||||
| 5-year OS | |||||
| sPD-L1 | >6.4 pg/mL | 12 | 13 | 0.0003 | 5.37 (2.14–13.42) |
| <6.4 pg/mL | 27 | 31 | |||
| CTCb | Positive | 16 | 6 | 0.003 | 4.61 (1.63–13.01) |
| Negativeb | 22 | 38 | |||
| Platinum‡ | Resistant | 4 | 9 | 0.007 | 5.48 (1.58–19.04) |
| Sensitive | 38 | 17 | |||
| (B) | |||||
| 5-year PFS | |||||
| sPD-L1 | >6.4 pg/mL | 34 | 6 | 0.0004 | 4.49 (1.61–12.47) |
| <6.4 pg/mL | 24 | 19 | |||
| CTCb | Positive | 19 | 3 | 0.046 | 3.67 (1.02–13.14) |
| Negativeb | 38 | 22 | |||
| Platinum‡ | Resistant | 13 | 0 | 0.003 | 21.00 (2.76–159.94) |
| Sensitive | 31 | 24 | |||
†
p-values were calculated by Fisher's exact test, OR, Odds ratio; CI, confidence interval.
‡
Platinum resistance was defined as recurrence <6 months after completion of adjuvant platinum therapy.
b
The presence of CTC in the blood was unknown for one patient.